Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.

about

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.

Item

http://www.wikidata.org/entity/Q50067496

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.

@en

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.

@nl

type

Item

label

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.

@en

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.

@nl

prefLabel

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.

@en

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.

@nl

P1476

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.

@en

P2093

Ege Altan

http://www.w3.org/2001/XMLSchema#string

Halis Şimşek

http://www.w3.org/2001/XMLSchema#string

Hayretdin Koklu

http://www.w3.org/2001/XMLSchema#string

Nomingerel Tseveldorj

http://www.w3.org/2001/XMLSchema#string

Tuğrul Pürnak

http://www.w3.org/2001/XMLSchema#string

P2860

A method for estimating the probability of adverse drug reactions

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.

Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.

Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

P304

1060028017742927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028017742927

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29126346

http://www.w3.org/2001/XMLSchema#string